Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Research & Development (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Research & Development for 8 consecutive years, with $98.2 million as the latest value for Q1 2026.

  • For Q1 2026, Research & Development rose 22.31% year-over-year to $98.2 million; the TTM value through Mar 2026 reached $334.5 million, up 23.11%, while the annual FY2025 figure was $316.6 million, 31.77% up from the prior year.
  • Research & Development hit $98.2 million in Q1 2026 for Kymera Therapeutics, up from $83.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $98.2 million in Q1 2026 and bottomed at $35.9 million in Q1 2022.
  • Average Research & Development over 5 years is $59.3 million, with a median of $53.0 million recorded in 2023.
  • Year-over-year, Research & Development rose 9.66% in 2023 and then skyrocketed 64.39% in 2025.
  • Kymera Therapeutics' Research & Development stood at $43.1 million in 2022, then rose by 22.81% to $53.0 million in 2023, then soared by 35.58% to $71.8 million in 2024, then grew by 16.73% to $83.8 million in 2025, then grew by 17.1% to $98.2 million in 2026.
  • According to Business Quant data, Research & Development over the past three periods came in at $98.2 million, $83.8 million, and $74.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.